Overview
Tirzepatide (LY3298176) is a synthetic peptide dual agonist targeting both the GLP-1 and GIP receptors. Unlike earlier single-axis GLP-1 receptor agonists, tirzepatide engages two incretin receptor systems simultaneously, making it a compound of significant interest in receptor pharmacology and metabolic signalling research.
It is supplied in lyophilised form for in vitro laboratory research use only.
The GLP-1 Receptor Axis
The glucagon-like peptide-1 receptor (GLP-1R) is a class B G protein-coupled receptor (GPCR) expressed across pancreatic beta cells, intestinal epithelium, and specific neuronal populations. GLP-1 receptor activation stimulates cyclic AMP production, triggering downstream kinase signalling cascades that regulate insulin secretion in a glucose-dependent manner.
In laboratory models, GLP-1R agonism is studied in pancreatic cell lines, neuronal cultures, and adipose tissue preparations, examining both acute and chronic receptor activation patterns.
The GIP Receptor Axis
The glucose-dependent insulinotropic polypeptide receptor (GIPR) is co-expressed with the GLP-1 receptor in pancreatic beta cells and is also found in adipose tissue and the central nervous system. GIPR activation is studied for its incretin potentiation effects — particularly how co-activation alongside GLP-1R may produce synergistic downstream signalling compared to single-receptor engagement.
Research into GIP receptor biology has historically been limited relative to GLP-1 work, making dual-agonist compounds an important tool for comparative receptor studies.
Dual Receptor Engagement in Research
The co-activation of both GLP-1R and GIPR by tirzepatide creates a distinct pharmacological profile compared to selective agonists. In vitro research examines how dual incretin receptor engagement modulates cAMP accumulation, beta-arrestin recruitment, and receptor internalisation differently from monoagonism.
Tirzepatide's GIP receptor affinity is reported to be higher than its GLP-1R affinity, a structural characteristic of interest to researchers studying bias in receptor signalling.
Research Applications
Tirzepatide is studied in laboratory settings including:
- Pancreatic beta cell and alpha cell function models
- Hypothalamic neuronal signalling assays
- Adipocyte differentiation and lipid metabolism models
- Hepatocyte glucose output studies
- Incretin receptor cross-talk and biased agonism research
All research applications are conducted in vitro. Tirzepatide supplied by Nova Biolabs is for laboratory research use only and is not intended for human or veterinary use.
Available from Nova Biolabs
Nova Biolabs supplies lyophilised tirzepatide in three vial sizes — 10mg, 20mg, and 40mg — held in UK domestic stock. All products are for laboratory research use only.